Porphyromonas gingivalis vaccines - gum disease is just the beginning...


13-09-2019
illustration of a tooth

This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Porphyromonas gingivalis vaccines.

Periodontal disease or 'gum disease' is a hugely prevalent inflammatory condition in adults affecting around two-thirds of the world population (mild/moderate and severe disease). The disease has become a global health concern and exerts substantial economic burden on healthcare systems due to the cost of surgical, dental treatment which, in many cases, can be suboptimal.

The bacterium Porphyromonas gingivalis (P. gingivalis) has been identified as a 'keystone' dysbiotic pathogen in periodontitis which causes impaired immunity through its interaction with the host complement system. The bacterium has a high prevalence in periodontitis patients and an association with alveolar bone loss. Research studies have demonstrated that specific blocking of P. gingivalis can reverse dysbiotic effects and protect against periodontal disease indicators, thereby implicating this mechanism as a potential therapy. In addition to its involvement in periodontal diseases, P. gingivalis also has a demonstrated association with many other chronic diseases such as cardiovascular, kidney, metabolic, respiratory disorders, cancer and has even more recently been implicated in Alzheimer's disease. Evidence for its association and potential involvement in the pathogenesis of these additional chronic conditions is further strengthening a hypothesis for its selective targeting with a therapeutic.

This MarketVIEW product contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of P. gingivalis vaccines across Western economies until 2040. The model contains value ($ m) and volume (million doses) predictions for an example vaccine-targeted priority segment along with timeframe, pricing and penetration estimates. The product also includes an in-depth review of periodontitis disease, epidemiology, treatments/guidelines and most recent developments in R&D (academic and commercial). It is an ideal “first pass” look at this intriguing therapeutic vaccine opportunity.

VacZine Analytics is an established strategic research agency based in the United Kingdom. Our aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit the website www.vacZine-analytics.com or contact info@vaczine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company No. 5807728

Copyright. All Rights Reserved, 2019

 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)